

NEUROENDOCRINE DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
 ROOM: ROSSETTI
 SATURDAY APRIL 28, 2018, 11:45 AM – 12:30 PM

CO-CHAIRS : DR. TIM ASMIS AND DR. SIMRON SINGH
 SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- *To interpret and address, through clinical and translational research, the disease burden associated with gastroenteropancreatic neuroendocrine malignancies in Canada.*
- *To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to gastroenteropancreatic neuroendocrine malignancies.*
- *To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to gastroenteropancreatic neuroendocrine malignancies.*
- *To interpret and apply new clinical trial methodologies in the field of clinical research in gastroenteropancreatic neuroendocrine malignancies.*

11:45 am	Setting Strategic Plan	Dr. T. Asmis Dr. S. Singh
	New Concepts in Development	
12:00 pm	TEMPTATION STUDY (AGITG): Temozolomide and Pembrolizumab Together to Increase Immunogenicity of Advanced Pancreatic Neuroendocrine Tumours	Dr. R. Goodwin
12:10 pm	A Phase II study of Avelumab In Addition to Radiotherapy in unresectable/metastatic, progressive Grade 2-3 Neuroendocrine Tumors	Dr. S. Myerhaug Dr. S. Singh
12:20 pm	COMMNETS – Commonwealth Neuroendocrine Tumour Collaboration	Dr. S. Singh
12:25 pm	Intergroup Task Force Update	Dr. T. Asmis
12:30 pm	Meeting Adjourned	